Skip to main content
Sana Biotechnology, Inc. logo

Sana Biotechnology, Inc. — Investor Relations & Filings

Ticker · SANA ISIN · US7995661045 US Manufacturing
Open in API
Filings indexed 362 across all filing types
Latest filing 2025-06-09 Director's Dealing
Country US United States of America
Listing US SANA

About Sana Biotechnology, Inc.

https://sana.com/

Sana Biotechnology, Inc. is a company that develops engineered cells as medicines to address the underlying causes of disease. Its core strategy involves two primary platforms: in vivo therapies designed to repair and control genes within a patient's existing cells, and ex vivo therapies that replace missing or damaged cells with new, functional ones. The company utilizes proprietary technologies, such as engineered fusogen proteins, for the targeted delivery of therapeutics. Sana's pipeline is focused on advancing drug candidates for a range of diseases, including diabetes, B-cell cancers, and B-cell related autoimmune disorders.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2025-06-09 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 8-K current report filed with the SEC, dated June 5, 2025, by Sana Biotechnology, Inc. The content focuses on the submission of matters to a vote of security holders at the company's 2025 annual meeting, including election of directors and ratification of the independent auditor. It provides detailed voting results for proposals presented at the Annual Meeting. This matches the description of Declaration of Voting Results & Voting Rights Announcements (DVA), which covers official results from shareholder votes at any general meeting. The document is not an Annual Report, Audit Report, or Proxy Statement, but specifically reports voting outcomes. The document length is under 5,000 characters and contains substantive voting data, so it is not merely an announcement of a report but the actual voting results report.
2025-06-06 English
424B5
Capital/Financing Update Classification · 95% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to a shelf registration statement on Form S-3. It details an offering of common stock up to $119 million, including terms of the offering, use of proceeds, risk factors, and plan of distribution. It is a detailed disclosure document for a capital raising event, specifically describing the terms and conditions of a stock offering. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. The document is not an annual or quarterly report, earnings release, or other regulatory filing type. It is not a report publication announcement since it contains substantive offering details rather than just announcing a report. Therefore, the correct classification is CAP with high confidence.
2025-05-08 English
S-8
Share Issue/Capital Change Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used to register securities to be offered under employee benefit plans such as incentive award plans. It includes details about the registration of additional shares under the 2021 Incentive Award Plan and incorporates by reference other filings like the Annual Report on Form 10-K and Quarterly Report on Form 10-Q. The document is not a financial report itself but a registration statement related to share issuance under an employee plan. Therefore, it fits the category of Share Issue/Capital Change announcements rather than an annual report or other financial filings.
2025-05-08 English
10-Q
Interim / Quarterly Report Q1 2025
2025-05-08 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 8, 2025, by Sana Biotechnology, Inc. It includes an Item 2.02 Results of Operations and Financial Condition section, which references a press release announcing financial results for the quarter ended March 31, 2025. It also includes Item 8.01 Other Events describing a new sales agreement for common stock, which is a capital raising activity. The document is a current report providing updates on financial results and capital financing activities, not a full annual or quarterly report. The presence of a sales agreement and discussion of stock sales indicates a capital/financing update. The document is not a full earnings release (ER) because it references a press release as an exhibit rather than containing the earnings highlights itself. It is not a report publication announcement since it contains substantive information about the sales agreement and financial results announcement. Therefore, the best classification is Capital/Financing Update (CAP).
2025-05-08 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.